View Older Stories
-
Puma Biotech (PBYI) Surges Following Results; Analyst Sees Few Excuses Not to Own
-
Puma Biotechnology (PBYI) PT Raised to $70 at Citi
-
Puma Biotechnology (PBYI) PT Lowered to $67 at Citi, Removed from Focus List
-
Survey Supports Puma Biotechnology (PBYI) Nerlynx Bull Case - Citi; PT Lowered to $151
-
Puma Biotechnology (PBYI) PT Raised to $164 at Citi
-
Buy the Puma Biotechnology (PBYI) Dip - Citi
-
Puma Biotech (PBYI): Added To The Focus List at Citi
-
Puma Biotechnology (PBYI) PT Lowered to $146 at Citi; 'Much Tougher Situation'
-
UPDATE: Puma Biotech (PBYI) Defended at Citi on FAERS News
-
Puma Biotechnology (PBYI) PT Raised to $164 at Citi, 'Buy The Dip'
-
Puma Biotechnology (PBYI) PT Raised to $156 at Citi
-
Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference
-
Puma Biotech (PBYI): Increasing PT But In Buyout, Would Be Worth $143 - Citi
-
Puma Biotech (PBYI) Is "shaping up as an attractive M&A target" - Citi
-
Puma Biotechnology (PBYI) PT Raised to $105 at Citi; Takeout Speculation Could Drive Shares Even Higher
-
Puma Biotechnology (PBYI) Briefing Documents 'Very Good' - Citi
-
Citigroup Defending Puma Biotech (PBYI), "Buy The Dip", Maintains Buy
-
Puma Biotech (PBYI) Said Defended at Citi
-
Puma Biotech (PBYI) Defended at Citi
-
Puma Biotechnology Closes $172 Million Public Offering of Common Stock
-
Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares
-
Puma Biotech (PBYI) Prices 3.75M Common Stock Offering at $40/Share
-
Puma Biotechnology Prices Public Offering of Common Stock
-
Puma Biotech (PBYI) Announces $150M Common Stock Offering
-
Puma Biotechnology Announces Proposed Public Offering of Common Stock
-
Pre-Open Stock Movers 09/22: (WCIC) (AVXL) (NVAX) Higher; (MLHR) (JBL) (CPK) Lower (more...)
-
Citi Highlights Potential Biotech M&A Names Following Relypsa Deal (ADRX) (OPHT) (PBYI) (PTLA) (RARE) (VSAR)
-
Pre-Open Stock Movers 03/29: (KERX) (OHRP) (CNL) Higher; (SUNE) (GEVO) (ALXA) Lower (more...)
-
Unusual 11 Mid-Day Movers 12/14: (NRX) (FXCM) (TSL) Higher; (PN) (ATRA) (GPRO) Lower
-
Citi Upgrades Puma Biotechnology (PBYI) to Buy
-
Citi Starts Puma Biotechnology (PBYI) at Neutral
-
Notable Analyst Rating Changes 5/5: (NFLX) (ALU) (ARRS) Upgraded; (BIDU) (AOL) (GNW) Downgraded
-
Three Small Cap Biotech Stocks Added to Citi's Most Preferred List (ATRA) (NVAX) (PBYI)
-
Puma Biotech (PBYI) Closes $205M Share Offering
-
Puma Biotech (PBYI) to Offer 1M Shares
-
Puma Biotechnology (PBYI) Adds to Gains as M&A Speculation Heats Up
-
UPDATE: Puma Biotechnology (PBYI) Price Target Raised to $292 at Citi, Stock Seen as Attractive Take-out Candidate
-
Notable Analyst Rating Changes 04/21: (MS) (AWI) (HNI) Upgraded; (WLT) (MGI) (YUM) Downgraded
-
Pre-Open Movers 4/21: (SRPT) (CBEY) (ASTM) Higher; (ATHN) (WLT) (PEIX) Lower (more...)
-
Citi Starts Puma Biotechnology (PBYI) at Buy
-
Puma Biotech (PBYI) Prices 979.6K Offering at $122.50/Share
-
Pre-Open Stock Movers 12/5: (CALI) (CBMX) (MEI) Higher; (SOL) (WTSL) (FRAN) Lower (more...)
-
After Hours Stock Movers 12/4: (PBYI) (MFRM) (GGP) Higher; (LGP) (SNPS) (ARO) Lower (more...)

